QTTB
Q32 Bio Inc.
-0.04 (-0.36%)10.94USD127K成交股數326M市值3.5本益比(近四季)6.0股價營收比-13.4%營收年增(近四季)–下次財報
內部人交易 SEC Form 4 · 董事、高階主管與持股 10% 以上股東 · 交易後兩個營業日內申報
買賣點與股價近一年
● 公開市場買進 · ● 公開市場賣出 · 空心 = 10b5-1 預設計畫(事先排程,不代表當下看法)。近一年,只畫 P / S 兩種代碼。
統計
| 近 90 天 買進筆數 · 金額 · 人數 | 0 · 0.00 · 0 |
|---|---|
| 近 90 天 賣出筆數 · 金額 · 人數 | 3 · 275K · 3 |
| 其中 10b5-1 計畫賣出 | 0 筆 |
| 近 180 天 買進 · 賣出金額 | 60.0M · 275K |
| 近 180 天 淨額 | 59.7M |
公開市場買進(P)是內部人自掏腰包,通常比賣出更有資訊含量 —— 賣出的理由很多(繳稅、分散、買房),買進的理由只有一個。
10b5-1 是事先排定的交易計畫,執行時點不反映當下看法。獲配股票(A)、繳稅扣股(F)、選擇權執行(M)是薪酬流程,不是意見。
| 交易日 | 申報日 | 申報人 | 職稱 | 代碼 | 股數 | 價格 | 金額 | 交易後持股 | 原件 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-25 | 08-27 | Violette Shelia M. | Chief Scientific Officer | S 公開市場賣出 | 2.8K | 16.56 | 46K | 128K | SEC |
| 2026-08-25 | 08-27 | Kalowski Lee | CFO and President | S 公開市場賣出 | 4.0K | 16.56 | 66K | 138K | SEC |
| 2026-08-25 | 08-27 | Morrison Jodie Pope | CEO | S 公開市場賣出 | 9.8K | 16.56 | 163K | 343K | SEC |
| 2026-07-16 | 07-20 | Kalowski Lee | CFO and President | A 獲配股票 | 53.3K | – | – | 142K | SEC |
| 2026-07-16 | 07-20 | Violette Shelia M. | Chief Scientific Officer | A 獲配股票 | 37.5K | – | – | 131K | SEC |
| 2026-07-16 | 07-20 | Morrison Jodie Pope | CEO | A 獲配股票 | 132K | – | – | 353K | SEC |
| 2026-06-30 | 07-02 | Manke Isaac | Director | M 選擇權執行 | 53.5K | 2.80 | 150K | 53.5K | SEC |
| 2026-05-28 | 06-01 | Xu Diyong | Director,TenPercentOwner | P 公開市場買進 | 625K | 8.00 | 5.0M | 625K | SEC |
| 2026-05-28 | 06-01 | OrbiMed Genesis GP LLC | Director,TenPercentOwner | P 公開市場買進 | 1.3M | 8.00 | 10.0M | 3.5M | SEC |
| 2026-05-28 | 06-01 | OrbiMed Genesis GP LLC | Director,TenPercentOwner | P 公開市場買進 | 625K | 8.00 | 5.0M | 625K | SEC |
| 2026-05-28 | 06-01 | OrbiMed Capital GP VII LLC | Director,TenPercentOwner | P 公開市場買進 | 625K | 8.00 | 5.0M | 625K | SEC |
| 2026-05-28 | 06-01 | OrbiMed Capital GP VII LLC | Director,TenPercentOwner | P 公開市場買進 | 1.3M | 8.00 | 10.0M | 3.5M | SEC |
| 2026-05-28 | 06-01 | ORBIMED ADVISORS LLC | Director,TenPercentOwner | P 公開市場買進 | 1.3M | 8.00 | 10.0M | 3.5M | SEC |
| 2026-05-28 | 06-01 | Xu Diyong | Director,TenPercentOwner | P 公開市場買進 | 1.3M | 8.00 | 10.0M | 3.5M | SEC |
| 2026-05-28 | 06-01 | ORBIMED ADVISORS LLC | Director,TenPercentOwner | P 公開市場買進 | 625K | 8.00 | 5.0M | 625K | SEC |
| 2026-02-25 | 02-27 | Morrison Jodie Pope | CEO | S 公開市場賣出 | 9.9K | 4.51 | 45K | 89.1K | SEC |
| 2026-02-25 | 02-27 | Kalowski Lee | CFO and President | S 公開市場賣出 | 4.0K | 4.51 | 18K | 35.9K | SEC |
| 2026-02-25 | 02-27 | Violette Shelia M. | Chief Scientific Officer | S 公開市場賣出 | 2.8K | 4.51 | 13K | 55.6K | SEC |
| 2026-02-24 | 03-20 | Morrison Jodie Pope | CEO | A 獲配股票 | 132K | – | – | 221K | SEC |
| 2026-02-24 | 03-20 | Kalowski Lee | CFO and President | A 獲配股票 | 53.3K | – | – | 89.2K | SEC |
| 2026-02-24 | 03-20 | Violette Shelia M. | Chief Scientific Officer | A 獲配股票 | 37.5K | – | – | 93.1K | SEC |
| 2025-12-02 | 12-04 | Kalowski Lee | CFO and President | S 公開市場賣出 | 9.1K | 3.46 | 31K | 39.9K | SEC |
| 2025-12-02 | 12-04 | Morrison Jodie Pope | CEO | S 公開市場賣出 | 22.5K | 3.46 | 78K | 99.0K | SEC |
| 2025-08-26 | 08-28 | Kalowski Lee | CFO and President | S 公開市場賣出 | 4.2K | 1.80 | 8K | 49.0K | SEC |
| 2025-08-26 | 08-28 | Morrison Jodie Pope | CEO | S 公開市場賣出 | 10.5K | 1.80 | 19K | 122K | SEC |
| 2025-08-26 | 08-28 | Violette Shelia M. | Chief Scientific Officer | S 公開市場賣出 | 3.0K | 1.80 | 5K | 58.4K | SEC |
| 2025-02-24 | 02-27 | Kalowski Lee | CFO and President | A 獲配股票 | 53.3K | – | – | 53.3K | SEC |
| 2025-02-24 | 02-26 | Morrison Jodie Pope | CEO | A 獲配股票 | 132K | – | – | 132K | SEC |
| 2025-02-24 | 02-26 | Campagna Jason | Chief Medical Officer | A 獲配股票 | 37.5K | – | – | 37.5K | SEC |
| 2025-02-24 | 02-26 | Violette Shelia M. | Chief Scientific Officer | A 獲配股票 | 37.5K | – | – | 61.4K | SEC |
| 2024-10-15 | 10-16 | Violette Shelia M. | Chief Scientific Officer | M 選擇權執行 | 6.0K | 7.29 | 44K | 23.9K | SEC |
| 2024-10-11 | 10-16 | Violette Shelia M. | Chief Scientific Officer | M 選擇權執行 | 4.6K | 3.12 | 14K | 17.9K | SEC |
| 2024-10-08 | 10-10 | Violette Shelia M. | Chief Scientific Officer | M 選擇權執行 | 13.3K | 3.12 | 41K | 13.3K | SEC |
| 2024-03-25 | 08-14 | TZIANABOS ARTHUR | Director | M 選擇權執行 | 1.1K | – | – | 8.2K | SEC |
| 2024-03-25 | 08-14 | TZIANABOS ARTHUR | Director | S 公開市場賣出 | 265 | 24.20 | 6K | 8.0K | SEC |
| 2024-03-25 | 04-23 | Alloway Paul | See Remarks | S 公開市場賣出 | 268 | 24.21 | 6K | 2.6K | SEC |
| 2024-03-25 | 04-23 | Michaud Charles Jr | See Remarks | S 公開市場賣出 | 75 | 24.20 | 2K | 927 | SEC |
| 2024-03-25 | 03-27 | Michaud Charles Jr | See Remarks | M 選擇權執行 | 6.4K | – | – | 18.0K | SEC |
| 2024-03-25 | 03-27 | Alloway Paul | See Remarks | M 選擇權執行 | 23.5K | – | – | 51.6K | SEC |
| 2024-01-09 | 02-15 | TZIANABOS ARTHUR | Director | S 公開市場賣出(10b5-1) | 13.0K | 0.57 | 7K | 129K | SEC |
| 2024-01-03 | 01-05 | Michaud Charles Jr | See Remarks | S 公開市場賣出 | 1.7K | 0.57 | 973.56 | 11.6K | SEC |
| 2024-01-03 | 01-05 | Alloway Paul | See Remarks | S 公開市場賣出 | 7.3K | 0.57 | 4K | 28.0K | SEC |
| 2024-01-01 | 02-15 | TZIANABOS ARTHUR | Director | M 選擇權執行 | 19.1K | – | – | 142K | SEC |
| 2024-01-01 | 02-15 | TZIANABOS ARTHUR | Director | M 選擇權執行 | 14.3K | – | – | 123K | SEC |
| 2024-01-01 | 01-03 | Alloway Paul | See Remarks | M 選擇權執行 | 4.4K | – | – | 21.1K | SEC |
| 2024-01-01 | 01-03 | Michaud Charles Jr | See Remarks | M 選擇權執行 | 544 | – | – | 9.6K | SEC |
| 2024-01-01 | 01-03 | Michaud Charles Jr | See Remarks | M 選擇權執行 | 2.6K | – | – | 13.3K | SEC |
| 2024-01-01 | 01-03 | Michaud Charles Jr | See Remarks | M 選擇權執行 | 1.1K | – | – | 10.7K | SEC |
| 2024-01-01 | 01-03 | Alloway Paul | See Remarks | M 選擇權執行 | 8.9K | – | – | 35.3K | SEC |
| 2024-01-01 | 01-03 | Alloway Paul | See Remarks | M 選擇權執行 | 5.3K | – | – | 26.4K | SEC |
| 2023-09-06 | 09-08 | Seymour Albert | See Remarks | S 公開市場賣出(10b5-1) | 1.4K | 1.15 | 2K | 151K | SEC |
| 2023-09-06 | 09-08 | Seymour Albert | See Remarks | M 選擇權執行 | 4.6K | – | – | 152K | SEC |
| 2023-08-03 | 08-07 | Jordan Julie | Chief Medical Officer | M 選擇權執行 | 1.5K | – | – | 4.3K | SEC |
| 2023-08-03 | 08-07 | Jordan Julie | Chief Medical Officer | S 公開市場賣出(10b5-1) | 436 | 1.39 | 606.04 | 3.9K | SEC |
| 2023-08-03 | 08-07 | Jordan Julie | Chief Medical Officer | S 公開市場賣出(10b5-1) | 1.3K | 1.39 | 2K | 7.5K | SEC |
| 2023-08-03 | 08-07 | Jordan Julie | Chief Medical Officer | M 選擇權執行 | 4.6K | – | – | 8.8K | SEC |
| 2023-08-03 | 08-07 | Jordan Julie | Chief Medical Officer | S 公開市場賣出(10b5-1) | 109 | 1.39 | 151.51 | 4.2K | SEC |
| 2023-08-03 | 08-07 | Jordan Julie | Chief Medical Officer | M 選擇權執行 | 387 | – | – | 4.3K | SEC |
| 2023-08-02 | 08-04 | Jordan Julie | Chief Medical Officer | S 公開市場賣出(10b5-1) | 99 | 1.31 | 129.69 | 2.8K | SEC |
| 2023-08-02 | 08-04 | Jordan Julie | Chief Medical Officer | M 選擇權執行 | 350 | – | – | 2.9K | SEC |
| 2023-03-02 | 03-06 | Alloway Paul | See Remarks | S 公開市場賣出 | 11.0K | 1.45 | 16K | 16.7K | SEC |
| 2023-01-09 | 01-11 | Seymour Albert | See Remarks | S 公開市場賣出 | 3.6K | 1.39 | 5K | 143K | SEC |
| 2023-01-09 | 01-11 | Smith W Bradford | See Remarks | S 公開市場賣出 | 3.7K | 1.39 | 5K | 14.2K | SEC |
| 2023-01-09 | 01-11 | TZIANABOS ARTHUR | Director | S 公開市場賣出 | 10.6K | 1.39 | 15K | 108K | SEC |
| 2023-01-09 | 01-11 | Alloway Paul | See Remarks | S 公開市場賣出 | 3.1K | 1.39 | 4K | 20.1K | SEC |
| 2023-01-09 | 01-11 | Blum Michael Lee | Chief Commercial Officer | S 公開市場賣出 | 2.5K | 1.39 | 3K | 13.5K | SEC |
| 2023-01-01 | 01-04 | Seymour Albert | See Remarks | M 選擇權執行 | 6.9K | – | – | 147K | SEC |
| 2023-01-01 | 01-04 | Smith W Bradford | See Remarks | M 選擇權執行 | 6.6K | – | – | 11.0K | SEC |
| 2023-01-01 | 01-04 | Blum Michael Lee | Chief Commercial Officer | M 選擇權執行 | 5.0K | – | – | 16.0K | SEC |
| 2023-01-01 | 01-04 | Alloway Paul | See Remarks | M 選擇權執行 | 5.3K | – | – | 23.2K | SEC |
| 2023-01-01 | 01-04 | Blum Michael Lee | Chief Commercial Officer | M 選擇權執行 | 2.6K | – | – | 11.0K | SEC |
| 2023-01-01 | 01-04 | TZIANABOS ARTHUR | Director | M 選擇權執行 | 19.1K | – | – | 119K | SEC |
| 2023-01-01 | 01-04 | TZIANABOS ARTHUR | Director | M 選擇權執行 | 13.9K | – | – | 99.9K | SEC |
| 2023-01-01 | 01-04 | Alloway Paul | See Remarks | M 選擇權執行 | 4.3K | – | – | 17.9K | SEC |
| 2023-01-01 | 01-04 | Seymour Albert | See Remarks | M 選擇權執行 | 4.3K | – | – | 140K | SEC |
| 2023-01-01 | 01-04 | Smith W Bradford | See Remarks | M 選擇權執行 | 6.9K | – | – | 17.9K | SEC |
| 2022-01-05 | 01-12 | Cohn Gabriel | Chief Medical Officer | S 公開市場賣出 | 1.7K | 3.78 | 6K | 2.6K | SEC |
| 2022-01-05 | 01-12 | TZIANABOS ARTHUR | President & CEO | S 公開市場賣出 | 5.4K | 3.78 | 20K | 86.0K | SEC |
| 2022-01-05 | 01-12 | Seymour Albert | Chief Scientific Officer | S 公開市場賣出 | 1.7K | 3.78 | 6K | 132K | SEC |
| 2022-01-05 | 01-12 | Kelly Timothy P | Chief Operating Officer | S 公開市場賣出 | 1.4K | 3.78 | 5K | 2.2K | SEC |
機構持股(13F) 管理規模 1 億美元以上的機構,每季末後 45 天內申報 · 最新 2026-06-30
前 25 大持有機構季末市值 · 與前一季股數比較
| 機構 | 持股 | 季末市值 | 股數季變化 | 動作 |
|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 4.1M | 52.6M | 新進 | 新進 |
| Boxer Capital Management, LLC | 3.1M | 40.1M | 新進 | 新進 |
| Atlas Venture Life Science Advisors, LLC | 2.7M | 34.6M | 新進 | 新進 |
| BVF INC/IL | 2.4M | 29.9M | 新進 | 新進 |
| RA CAPITAL MANAGEMENT, L.P. | 2.3M | 29.7M | 新進 | 新進 |
| Point72(柯恩) Point72 Asset Management, L.P. | 1.2M | 14.9M | 新進 | 新進 |
| Opaleye Management Inc. | 931K | 11.9M | 新進 | 新進 |
| Logos Global Management LP | 800K | 10.2M | 新進 | 新進 |
| SummitTX Capital, L.P. | 734K | 9.3M | 新進 | 新進 |
| VANGUARD CAPITAL MANAGEMENT LLC | 519K | 6.6M | 新進 | 新進 |
| Ikarian Capital, LLC | 430K | 5.5M | 新進 | 新進 |
| Woodline Partners LP | 286K | 3.6M | 新進 | 新進 |
| AMERICAN CENTURY COMPANIES INC | 273K | 3.5M | 新進 | 新進 |
| Sanofi | 244K | 3.1M | 新進 | 新進 |
| ACORN CAPITAL ADVISORS, LLC | 216K | 2.8M | 新進 | 新進 |
| 文藝復興 RENAISSANCE TECHNOLOGIES LLC | 180K | 2.3M | 新進 | 新進 |
| JANE STREET GROUP, LLC | 163K | 2.1M | 新進 | 新進 |
| MONIMUS CAPITAL MANAGEMENT, LP | 132K | 1.7M | 新進 | 新進 |
| BOOTHBAY FUND MANAGEMENT, LLC | 130K | 1.7M | 新進 | 新進 |
| GEODE CAPITAL MANAGEMENT, LLC | 123K | 1.6M | 新進 | 新進 |
| 城堡 CITADEL ADVISORS LLC | 121K | 1.5M | 新進 | 新進 |
| BlackRock, Inc. | 119K | 1.5M | 新進 | 新進 |
| MARSHALL WACE, LLP | 67.0K | 854K | 新進 | 新進 |
| VANGUARD FIDUCIARY TRUST CO | 66.2K | 844K | 新進 | 新進 |
| Carlyle Group Inc. | 60.4K | 769K | 新進 | 新進 |
持有機構數近 12 季
每季 13F 申報中持有本股的機構家數;綠柱 = 比上季少。機構數是「有多少人在船上」,不是「買了多少」。
| 持有機構 · 季變化 | 71 +18 |
|---|---|
| 新進 / 出清 / 加碼 / 減碼 | 71 / 0 / 0 / 0 |
| 機構合計持股 · 佔流通股 | 22.2M · 74.6% |
| 合計季末市值 | 279M |
13F 只申報多頭部位(含可轉債與選擇權,選擇權這裡已排除),不申報放空,也不申報 1 億美元以下的機構。同一集團多個申報主體會各算一家。
放空餘額 FINRA 每月兩次(15 日與月底結算)· 最新 2026-08-31
空單佔流通股近 13 個月
FINRA 每月兩次結算的空單餘額佔流通股數的比例,近 13 個月。滑到柱子看股數與回補天數。
最新一期
| 空單股數 | 3.6M |
|---|---|
| 與上期比 | +13.3% |
| 佔流通股數 | 11.95% |
| 日均成交量 | 373K |
| 回補天數 | 9.5 天 |
空單佔比 10% 以上算高、20% 以上算很高(這是通行的說法,不是本站的判斷)。回補天數 = 空單 ÷ 日均量,天數愈長,空方要出場時愈容易推升股價。
放空餘額是「有人借股票賣掉還沒還」的存量,不代表看空的人正在加碼;避險基金做多空配對時也會產生空單。
| 結算日 | 空單股數 | 與上期比 | 佔流通股 | 日均量 | 回補天數 |
|---|---|---|---|---|---|
| 2026-08-31 | 3.6M | +13.3% | 11.95% | 373K | 9.5 |
| 2026-08-14 | 3.1M | +4.6% | 10.54% | 458K | 6.9 |
| 2026-07-31 | 3.0M | +32.6% | 10.08% | 795K | 3.8 |
| 2026-07-15 | 2.3M | +234.3% | 7.60% | 4.1M | 1.0 |
| 2026-06-30 | 677K | -25.3% | 2.27% | 421K | 1.6 |
| 2026-06-15 | 906K | +5.2% | 3.04% | 650K | 1.4 |
| 2026-05-29 | 862K | +36.2% | 2.89% | 2.8M | 1.0 |
| 2026-05-15 | 633K | -3.1% | 2.13% | 237K | 2.7 |
| 2026-04-30 | 653K | +70.7% | 2.19% | 395K | 1.7 |
| 2026-04-15 | 382K | -7.0% | 1.28% | 315K | 1.2 |
| 2026-03-31 | 411K | +17.3% | 1.38% | 341K | 1.2 |
| 2026-03-13 | 351K | -3.2% | 1.18% | 306K | 1.1 |
| 2026-02-27 | 362K | -1.0% | 1.22% | 125K | 2.9 |
| 2026-02-13 | 366K | +18.4% | 1.23% | 175K | 2.1 |
| 2026-01-30 | 309K | +16.5% | 1.04% | 184K | 1.7 |
| 2026-01-15 | 265K | -6.1% | 0.89% | 155K | 1.7 |
| 2025-12-31 | 282K | -34.3% | 0.95% | 166K | 1.7 |
| 2025-12-15 | 429K | +45.3% | 1.44% | 15.9M | 1.0 |
| 2025-11-28 | 295K | +6.3% | 0.99% | 60.5K | 4.9 |
| 2025-11-14 | 278K | +1.8% | 0.93% | 78.2K | 3.6 |
| 2025-10-31 | 273K | -41.3% | 0.92% | 170K | 1.6 |
| 2025-10-15 | 465K | +67.2% | 1.56% | 832K | 1.0 |
| 2025-09-30 | 278K | -3.7% | 0.93% | 68.9K | 4.0 |
| 2025-09-15 | 288K | -6.0% | 0.97% | 65.8K | 4.4 |
| 2025-08-29 | 307K | -13.8% | 1.03% | 94.6K | 3.3 |
| 2025-08-15 | 356K | -13.7% | 1.20% | 175K | 2.0 |